EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real‐world radical cystectomy use in high‐risk non‐muscle‐invasive bladder cancer: a global survey

Jose Luis Dominguez Escrig, Peter Black, Junichi Inokuchi iD, Girish Kulkarni, Wei Qiang iD, Bao Yige, Lucy Andersen iD, Sarah Côté, Ruhee Jain, Brendan Osborne iD, Marie Deault-Bonin, Siobhán Mulhern Haughey und 5 weitere

BJU International · 2026-12 · 138 (6) · 1043-1052

DOI: 10.1111/bju.70480 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 02.10.2026. Verfasst von Jose Luis Dominguez Escrig und 16 weiteren Autor:innen. Beteiligte Einrichtung: Jefe Clínico Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain. Hauptthemen laut MEDLINE: Cystectomy, Non-Muscle Invasive Bladder Neoplasms, Practice Patterns, Physicians', Urinary Bladder Neoplasms. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate real‐world utilisation of radical cystectomy (RC), its acceptance and limitations, and physician perspectives on RC in patients with high‐risk non‐muscle‐invasive bladder cancer (HR‐NMIBC). Patients/Subjects and Methods Data were obtained from the Adelphi Disease Specific Programme™, a multinational, cross‐sectional survey of urologists and medical oncologists treating patients with HR‐NMIBC in China, Japan, Canada, France, Germany, Italy, Spain, and the UK. Physicians reported patient demographics, clinical characteristics, treatment patterns, and patient preferences regarding HR‐NMIBC treatment and surgery.

Results

Overall, 359 physicians provided data for 2583 patients (mean [standard deviation] patient age, 68.9 [9.8] years; 74% male; Stage‐1 [T1] high‐grade tumours 68%). Bacillus Calmette–Guérin (BCG) was used as first‐line treatment in 58% ( n = 1487) of patients. Among patients with recurrent HR‐NMIBC, RC was used in 8% (62 of 802), 7% (13 of 188), and 8% (four of 52) at second line‐of‐treatment, third line‐of‐treatment, and fourth line‐of‐treatment, respectively. Physicians considered 24% of patients likely future RC candidates. Further data were collected on 825 patients who received BCG treatment. Among these patients, RC was offered to 169 (20%); 115 of these patients (68%) refused, most commonly because of quality‐of‐life concerns (87%), unwillingness to have a stoma (60%), and surgical safety concerns (37%).

Conclusion

Despite guideline recommendations, real‐world RC use was low, and most patients offered RC refused it because of quality‐of‐life and safety concerns. These findings highlight an unmet need for alternative and efficacious bladder‐preserving treatments for patients with BCG‐unresponsive HR‐NMIBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CystectomyNon-Muscle Invasive Bladder NeoplasmsPractice Patterns, Physicians'Urinary Bladder NeoplasmsHumansMaleAgedCross-Sectional StudiesFemaleMiddle AgedSurveys and Questionnaires

Stichwörter der Autor:innen

bladder cancerbladder‐sparingradical cystectomyreal‐worldsurveytreatment patterns

Autor:innen und Institutionen

  • Jefe Clínico Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
  • Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
  • Gordon & Leslie Diamond Health Care Centre & Vancouver General Hospital, Vancouver, British Columbia, Canada.
  • Department of Urology, Graduate School of Medicine, University of the Ryukyus, Ginowan, Okinawa, Japan.
  • Division of Urology and Surgical Oncology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

ORCID-Profile: Junichi Inokuchi, Wei Qiang, Lucy Andersen, Brendan Osborne, Laure Manuel, Christopher J D Wallis

Förderung

  • Johnson and Johnson

Zitieren

APA

Escrig, J. L. D., Black, P., Inokuchi, J., Kulkarni, G., Qiang, W., Yige, B., Andersen, L., Côté, S., Jain, R., Osborne, B., Deault-Bonin, M., Haughey, S. M., Biondi, E., Manuel, L., Skilling, J., Unsworth, M., & Wallis, C. J. D. (2026). Real‐world radical cystectomy use in high‐risk non‐muscle‐invasive bladder cancer: a global survey. BJU International, 138(6), 1043-1052. https://doi.org/10.1111/bju.70480

Vancouver

Escrig JLD, Black P, Inokuchi J, Kulkarni G, Qiang W, Yige B, et al. Real‐world radical cystectomy use in high‐risk non‐muscle‐invasive bladder cancer: a global survey. BJU International. 2026;138(6):1043-1052. doi:10.1111/bju.70480

BibTeX
@article{Escrig2026,
  author = {Escrig, Jose Luis Dominguez and Black, Peter and Inokuchi, Junichi and Kulkarni, Girish and Qiang, Wei and Yige, Bao and Andersen, Lucy and Côté, Sarah and Jain, Ruhee and Osborne, Brendan and Deault-Bonin, Marie and Haughey, Siobhán Mulhern and Biondi, Emilia and Manuel, Laure and Skilling, Jacob and Unsworth, Mia and Wallis, Christopher J D},
  title = {Real‐world radical cystectomy use in high‐risk non‐muscle‐invasive bladder cancer: a global survey},
  journal = {BJU International},
  year = {2026},
  volume = {138},
  number = {6},
  pages = {1043--1052},
  doi = {10.1111/bju.70480}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche